We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TROD Medical Receives CE Mark Approval for Encage™
News

TROD Medical Receives CE Mark Approval for Encage™

TROD Medical Receives CE Mark Approval for Encage™
News

TROD Medical Receives CE Mark Approval for Encage™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TROD Medical Receives CE Mark Approval for Encage™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TROD Medical NV has announced that it has received CE Mark Approval for its Encage™ device.

“Receiving CE Mark Approval for Encage™ is a major milestone for the Company” said Andre Faure, CEO of TROD Medical, “and builds on the US FDA 510(k) clearance secured in 2008.”

TROD Medical’s Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. Encage is a breakthrough in treatment for prostate cancer, one of the most common soft tissue cancers in the world with around 240,000 new cases every year in the US alone.

Encage has the potential to reduce the risk of side effects commonly associated with current treatments, including erectile dysfunction (impotence), and urinary and fecal incontinence.

Advertisement